This is a post hoc analysis of a multi-country study of adults with type 2 diabetes transitioned from basal-only to basal-bolus insulin therapy. Patients were randomized 1:1 to deliver mealtime insulin using either a wearable delivery device (PAQ Meal) or a pen (NovoLog FlexPen®). We report the proportion of patients overall who achieved A1C ≤8% and A1C ≤7% by Week 24 and sustained the improvement through Week 44 when using a basal-bolus regimen. Baseline A1C ranged from 7.0 - 11.8% (patients, n=274). By week 24, 84.7% (232/274) of patients achieved A1C ≤ 8% (LOCF) which continued at 84.8% (184/217 completers) at Week 44. Overall, 77.9% (169/217) of patients saw a reduction of at least 1% in A1C by Week 44. Although, patients with higher baselines achieved a greater reduction of A1C, patients with lower baselines were significantly more likely to achieve A1C ≤ 7%. Reduction in A1C ≤ 7% was sustained by 63.6% (138/217) of patients through Week 44. Initiating a basal-bolus regimen and titrating based on morning and mealtime blood glucose levels saw the mean total daily dose increase from 47IU (basal only) at study entry to 121IU (basal-bolus) at Week 24 (0.8:1 basal:bolus). Only 6 severe hypoglycemic events occurred during the study. This study shows that transitioning from basal insulin-alone to basal-bolus insulin therapy, regardless of delivery mechanism, safely reduces and manages A1C levels in T2DM patients.


R. Barry: Consultant; Self; CeQur Corporation. D. Johns: Consultant; Self; CeQur Corporation. B. Rees: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at